The VGLL1 (Vestigial-like family member 1) antibody is a tool used to detect and study the VGLL1 protein, a transcriptional co-regulator involved in developmental and oncogenic processes. VGLL1 belongs to the VGLL family, which shares structural homology with the Drosophila vestigial protein, a key regulator of wing development. In humans, VGLL1 acts as a co-activator or co-repressor, interacting with transcription factors such as TEAD (Transcriptional Enhanced Associate Domain) to modulate gene expression linked to cell proliferation, differentiation, and tissue homeostasis. It plays roles in embryonic development, tissue repair, and cancer progression, with studies highlighting its overexpression in cancers like ovarian, breast, and hepatocellular carcinoma, where it may promote tumor growth and metastasis.
VGLL1 antibodies are essential for investigating its expression patterns, subcellular localization, and molecular interactions in both normal and pathological contexts. These antibodies are validated for techniques including Western blotting, immunohistochemistry (IHC), immunofluorescence (IF), and co-immunoprecipitation (Co-IP). Researchers utilize VGLL1-specific antibodies to explore its role in the Hippo signaling pathway, its crosstalk with other oncogenic pathways, and its potential as a therapeutic target or biomarker. Commercial VGLL1 antibodies are typically raised against epitopes within its conserved TDU domain or unique N/C-terminal regions, with validation in relevant cell lines and tissues ensuring specificity.